Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Unasnemab in Healthy Japanese Males
NCT05396235Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Aug 2022
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in spinal cord injury (SCI) comparing MT-3921 with Placebo (2 arms). Primary endpoints: Percentage of subjects with adverse events at 16 weeks, Percentage of subjects with adverse reactions at 16 weeks and 1 more. Started Aug 2022; status: completed.
02
Drugs
unasnemab
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT05396235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05396235.